Evidence map›Paper›PMID 37543918›Full record

ArticleArchives of Iranian medicine2023

Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran.

Leila Rahmati, Alireza Mooghali, Seyed Mohammad Hosein Kamani, Fatemeh Zare, Hassan Askari, Ali Reza Safarpour

Open access · hybridAbstract read
In one paragraph

Article in Archives of Iranian medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Leila RahmatiGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Department of Management, Payame Noor University, Tehran, Iran.ORCID 0000-0003-4529-6768
Alireza MooghaliDepartment of Management, Payame Noor University, Tehran, Iran.
Seyed Mohammad Hosein KamaniDepartment of Management, Payame Noor University, Tehran, Iran.
Fatemeh ZareDepartment of Research Deputy, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hassan AskariGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Department of Management, Payame Noor University, Tehran, Iran.ORCID 0000-0002-2285-2592
Ali Reza SafarpourGastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Department of Management, Payame Noor University, Tehran, Iran.ORCID 0000-0002-9880-0043
Shiraz University of Medical Sciences · IRPayame Noor University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe epidemiological burden of chronic diseases and their risk factors is increasing all over the world, especially in developing and low-income countries. Inflammatory bowel disease (IBD) is one of the chronic diseases which has imposed a great financial burden on individuals and the society.

objectivesThe current study aimed at estimating the economic burden of IBD among 90 patients with IBD who referred to Namazi hospital and Motahari clinic of Shiraz in 2019. The costs to patients were monitored for a year to detect their expenses.

methodsThis study is descriptive cross-sectional and from a social perspective. The cost-of-illness method, based on the human capital theory, has been used. Both direct and indirect costs have been estimated using a prevalence approach and bottom-up method. Hospital costs were extracted from patients' records and the accounting system of Namazi Hospital. Outpatient expenses were obtained according to the number of outpatient visits and the average cost of visit were obtained by interviewing patients. Socio-economic status, medical expenses and number of days absent from work were determined using a valid and reliable questionnaire. Assessment of the cost of hospital care was made on the basis of the average daily. Non-medical direct costs such as transportation and residence, etc. were also calculated.

resultsThe total annual economic costs of IBD per patient were estimated at 1229.74 USD. Finally, increased use of health care as well as lost productivity leads to increased disease costs.

conclusionIBD imposes a substantial economic burden on patients, families and the society. Establishing a correct diagnosis early, management of IBD worsening, and appropriate treatment can reduce the costs of treatment and lost production to some extent. Therefore, policymakers should take this into consideration and according to available health resources, provide services and facilities for the prevention and treatment of the disease.

Indexed as

Health Care CostsInflammatory Bowel DiseasesCost of IllnessCross-Sectional StudiesFinancial StressHumansIranDirect costsEconomic burdenIndirect costsInflammatory bowel diseases

Identifiers

PMID37543918
PMCPMC10685812
OpenAlexW4380366697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.